{
  "profile_url": "https://www.moffitt.org/research-science/researchers/jhanelle-gray",
  "last_updated": "2025-10-19T00:29:17.379988",
  "researcher_id": "3726",
  "degrees": [
    "MD"
  ],
  "title": "",
  "primary_program": "Thoracic Oncology",
  "research_program": "Molecular Medicine Program",
  "overview": "My research focus is to evaluate new molecular targets and biomarkers in lung cancer to reduce chemotherapy resistance and advance patient-specific therapy.",
  "research_interests": [
    "Dr. Gray\u2019s research focuses on the analysis of targeted therapies in patients with non-small cell lung cancer (NSCLC) and those at risk for lung cancer with hopes of optimizing the therapeutic benefit while minimizing the toxicity with the use of biomarker analysis to enhance the understanding of cancer biology and treatment.She was the principal investigator of a phase IIB randomized, placebo-controlled, double-blind study of enzastaurin (a protein kinase C inhibitor), investigating its efficacy in lung cancer prevention in former smokers. Through her continued work on this project, she was awarded an NIH Specialized Program of Research Excellence (SPORE) supplement grant (Research Supplements to Promote Diversity in Health-Related Research). Additionally Dr. Gray is involved in analyzing histone deacetylase (HDAC) inhibitors as a novel treatment approach in patients with lung cancer. One strategy to enhance the efficacy of the EGFR tyrosine kinase inhibitor, already demonstrated in vitro, is to combine erlotinib with inhibitors of other key oncogenic pathways such as HDAC inhibitors. Dr. Gray and colleagues also are exploring additional HDAC inhibitor combination strategies for clinical application.\n  *"
  ],
  "associations": [
    "Thoracic Oncology",
    "Tumor Microenvironment and Metastasis",
    "Lung Cancer Center of Excellence",
    "Molecular Medicine Program",
    "Experimental Therapeutics Program",
    "Cancer Chemoprevention Research Interest Group",
    "Melanoma & Skin Cancer Center of Excellence"
  ],
  "education": [
    {
      "type": "Medical School",
      "institution": "Weill Medical College of Cornell University, New York, NY",
      "degree": "MD"
    },
    {
      "type": "Residency",
      "institution": "The New York Presbyterian Hospital, New York, NY",
      "specialty": ""
    },
    {
      "type": "Fellowship",
      "institution": "H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL",
      "specialty": "Hematology/Oncology"
    },
    {
      "type": "Board Certification",
      "institution": "Internal Medicine",
      "certification": "Medical Oncology"
    },
    {
      "type": "Board Certification",
      "institution": "Internal Medicine",
      "certification": "Hematology"
    }
  ],
  "publications": [
    {
      "title": "Garassino MC, Cheng Y, Rodriguez-Abreu D, Novello S, Mazieres J, Robinson AG, Powell SF, Halmos B, Gray JE, Wang M, Chen C, Yang J, Souza F, Schwarzenberger P, Paz-Ares L. Impact of Tumor Response and Response Duration on Survival Among Participants Receiving Pembrolizumab Plus Chemotherapy as First-Line Therapy for Non-Small-Cell Lung Cancer. Oncol Ther",
      "pubmed_id": "40498298",
      "pmc_id": "PMC12378254",
      "year": "2025",
      "journal": "13(3):667-681",
      "authors": ""
    },
    {
      "title": "Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ, Redman MW, Carrizosa DR, Wang WL, Petty WJ, Mehta K, Faller BA, Agamah ES, Kasbari SS, Malisetti RK, Kumar A, Schallenkamp J, Alluri KC, Gray JE, Kelly K. Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab Plus Talazoparib in Patients With SLFN11 Positive Extensive-Stage SCLC: S1929. J Thorac Oncol",
      "pubmed_id": "39505259",
      "year": "2025",
      "journal": "20(3):383-394",
      "authors": ""
    },
    {
      "title": "Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabb\u00f3 F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Leighl NB, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, J\u00e4nne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV. Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. N ..."
    },
    {
      "title": "Murat-Onana ML, Ramalingam SS, J\u00e4nne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer",
      "pubmed_id": "40311309",
      "year": "2025",
      "journal": "204:108549",
      "authors": ""
    },
    {
      "title": "Gray JE, Salomonsen RJ, Diaz Perez I, Wang A, Cai L, Wetherill G, Xiao Y, Fielden C, Georgoulia N. Real-World Clinical Characteristics, Treatment Patterns, and Clinical Outcomes in US Patients with Stage I-III Resected NSCLC Without Known EGFR Mutations: The RESECT Study. Drugs Real World Outcomes",
      "pubmed_id": "40329045",
      "pmc_id": "PMC12174031",
      "year": "2025",
      "journal": "12(2):175-188",
      "authors": ""
    },
    {
      "title": "Tanvetyanon T, Joshi U, Chen DT, Gray JE. Timeliness of Newer Targeted Therapy and Survival in Lung Cancer: A Population-Based Analysis. JCO Oncol Pract",
      "pubmed_id": "40472300",
      "year": "2025",
      "journal": "OP2400936",
      "authors": ""
    },
    {
      "title": "Orr LD, Vanderpoel J, Vadagam P, Patel MI, Roy UB, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Patient, care partner, and provider voice in treatment decision-making for non-small cell lung cancer. Patient Educ Couns",
      "pubmed_id": "40215576",
      "year": "2025",
      "journal": "136:108776",
      "authors": ""
    },
    {
      "title": "Nassar AH, Jayakrishnan R, Feng J, Shepherd F, Adib E, Cheung JM, Lin JJ, Liu Y, Lin SH, Parikh K, Sridhar A, Shakya P, Dilling TJ, Kaldas D, Gray JE, Lobachov A, Bar J, Luders H, Grohe C, Gupta S, Leal T, Fitzgerald B, Crowley F, Fujiwara Y, Marron TU, Wilgucki M, Reuss J, Chen L, Sankar K, Aredo JV, Neal JW, Wakelee HA, Thummalapalli R, Yu H, Whitaker R, Velazquez A, Ragavan M, Cortellini A, Kwiatkowski DJ, Naqash AR, Goldberg SB, Kim SY. Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC. J Thorac Oncol",
      "pubmed_id": "39260522",
      "year": "2025",
      "journal": "20(1):109-118",
      "authors": ""
    },
    {
      "title": "Hochmair M, Schenker M, Dols MC, Kim TM, Ozyilkan O, Smagina M, Viktoriya L, Kato T, Fedenko A, De Angelis F, Rittmeyer A, Gray JE, Greystoke A, Aggarwal H, Huang Q, Zhao B, Lara-Guerra H, Nadal E. Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy. J Thorac Oncol",
      "pubmed_id": "39477187",
      "year": "2025",
      "journal": "20(2):203-218",
      "authors": ""
    },
    {
      "title": "Gray JE, Schenker M, Nahit \u015eendur MA, Leonova V, Kowalski D, Kato T, Orlova R, Chih-Hsin Yang J, Langleben A, Pilz A, Ungureanu A, Mak MP, Flavia De Angelis, Aggarwal H, Zimmer Z, Zhao B, Shamoun M, Kim TM. The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC. J Thorac Oncol",
      "pubmed_id": "39521434",
      "year": "2025",
      "journal": "20(2):219-232",
      "authors": ""
    }
  ],
  "grants": [
    {
      "description": "Title: Modernize Adverse Event (AE) Data to Develop Predictive AE Biomarkers for Fulfilling Oncological Precision Medicine  \nAward Number: MOAAX  \nSponsor: Florida Department of Health  \nChen, D. (PD/PI), Gray, J. (Co-PD/PI)"
    },
    {
      "description": "Title: Community Outreach to Empower Black Patients with NSCLC to Improve Engagement and Awareness (COMPASS)  \nAward Number:   \nSponsor: FOUNDATION MEDICINE INC.  \nGray, J. (PD/PI)"
    },
    {
      "description": "Title: Community Project Funding/Congressionally Directed Spending Construction - Mobile Lung Screening Program  \nAward Number: 1CE1HS52205?01?00  \nSponsor: Health Resources and Services Administration (HRSA)  \nGray, J. (PD/PI)"
    },
    {
      "description": "Title: Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer  \nAward Number: 1R01CA253312-01  \nSponsor: National Cancer Institute (NCI)  \nGray, J. (PD/PI)",
      "source": "NCI",
      "period": "3312-01"
    },
    {
      "description": "Title: Southwest Oncology Group (SWOG) Appointment  \nAward Number: 5U10CA180888-11 Revised  \nSponsor: National Cancer Institute (NCI)  \nGray, J. (PD/PI)",
      "source": "NCI",
      "period": "0888-11"
    },
    {
      "description": "Title: Cancer Trials Support Unit (CTSU) Phase II Supplemental Payments - Master Lung Protocol  \nAward Number: HHSN26120622012C  \nSponsor: National Cancer Institute (NCI)  \nGray, J. (PD/PI)",
      "source": "NCI"
    }
  ],
  "photo_url": "https://www.moffitt.org/globalassets/images/researchers_bio/GrayJhanelle_3726.jpg",
  "contact": {
    "contact_url": "https://eforms.moffitt.org/ContactResearchersForm?PERID=3726"
  },
  "content_hash": "5712b385cca898998bc387de9f79a3a003d023f34252e77bd9d0faadff92d329",
  "researcher_name": "Jhanelle Gray",
  "department": "Tumor Microenvironment and Metastasis"
}